Previous Close | 23.93 |
Open | 23.63 |
Bid | 0.00 x 800 |
Ask | 23.07 x 900 |
Day's Range | 22.33 - 23.63 |
52 Week Range | 19.45 - 67.84 |
Volume | |
Avg. Volume | 15,880 |
Market Cap | 1.237B |
Beta (5Y Monthly) | 0.98 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.49 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 48.43 |
Subscribe to Yahoo Finance Plus to view Fair Value for VALN
Saint Herblain (France), May 25, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the successful completion of the lot-to-lot Phase 3 trial of its single-shot chikungunya vaccine candidate, VLA1553. The final analysis included six-month follow-up data and confirmed the topline results reported in December 2021. The VLA1553-302 trial met its primary endpoint, demonstrating that three consecutively manufactured vaccine lots elicited equivalent imm
Dynavax (DVAX) gains as the EMA accepts partner Valneva's MAA for COVID-19 vaccine.
What happened Several days after experiencing a pleasant share price pop on good regulatory news, Dynavax (NASDAQ: DVAX) repeated the feat on Thursday. An important partner for the company reported an encouraging development that morning, also in the regulatory sphere.